Stocks · News reference
iSpecimen Inc. has completed the acquisition of two artificial intelligence products from Foldlab AI Ltd. to enter the AI-powered disease intelligence market.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-09 AccNo: 0001213900-26-117610 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
iSpecimen Inc. stockholders have approved a proposal authorizing a reverse stock split at a ratio between 1-for-10 and 1-for-100.
iSpecimen Inc. has expanded its marketplace to include next-day delivery of prospectively collected healthy donor whole blood and announced plans to develop AI-powered search capabilities for its inventory.
Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus
iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
On September 4, 2026, iSpecimen Inc., a Delaware corporation (the "Company"), entered into an Asset Purchase Agreement (the "Agreement") with Foldlab AI Ltd., a company organized under the laws of